Boston Scientific stock rebounds as analysts see double-digit upside
Published on 08/22/2026 at 13:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific Corp. (ISIN US10117L1017) stock closed at $50.37 on August 21, 2026, gaining 2.03 percent in a rebound that recaptured 38 percent of the previous session's losses, according to a market recap reported by S&P Global data collected by StockAnalysis in an article hosted on ts2.tech title='TS2.Tech on Boston Scientific rebound' href='https://ts2.tech/en/boston-scientific-rebounds-2-recovering-38-of-thursdays-selloff/'>the TS2.Tech market wrap.
Analyst targets still point to upside
The same TS2.Tech overview shows that the consensus target price for Boston Scientific stood at $62.69 in August 2026, implying an upside of 24.46 percent from the $50.37 close as of August 21, 2026 S&P Global data collected by StockAnalysis in an article hosted on ts2.tech title='TS2.Tech on Boston Scientific analyst targets' href='https://ts2.tech/en/boston-scientific-rebounds-2-recovering-38-of-thursdays-selloff/'>according to the analyst summary.
Within that consensus, the median target was $60, with individual forecasts ranging from $44 to $94 per share, highlighting a wide dispersion of views but a clear central tendency above the current trading level S&P Global data collected by StockAnalysis in an article hosted on ts2.tech title='TS2.Tech on Boston Scientific target range' href='https://ts2.tech/en/boston-scientific-rebounds-2-recovering-38-of-thursdays-selloff/'>as shown in the target range table.
Institutional flows reinforce interest
Fresh regulatory filings summarized on MarketBeat title='MarketBeat on institutional flows in Boston Scientific' href='https://www.marketbeat.com/instant-alerts/filing-encore-global-management-lp-invests-315-million-in-boston-scientific-corporation-bsx-2026-08-21/'>a Boston Scientific alert indicate that institutional investors have been adding to positions, including a disclosed $3.15 million investment from a fund manager in August 2026.
Those same filings list Boston Scientific shares opening at $50.39 on the most recent trading day referenced, which is consistent with the $50.37 official close reported by TS2.Tech for August 21, 2026 and underscores the modest intraday volatility around the rebound level S&P Global data collected by StockAnalysis in an article hosted on ts2.tech title='TS2.Tech on Boston Scientific August 21 quote' href='https://ts2.tech/en/boston-scientific-rebounds-2-recovering-38-of-thursdays-selloff/'>in the price recap.
For investors, the combination of renewed institutional buying and a consensus target that still sits more than $12 above the latest close suggests that the market is pricing in continued earnings and device momentum, even after the recent two-session swing.
Recent trading pattern and volume
The TS2.Tech market report notes that Boston Scientific traded 31.8 million shares on August 21, 2026, a volume spike that accompanied the 2.03 percent rebound from the prior day's selloff S&P Global data collected by StockAnalysis in an article hosted on ts2.tech title='TS2.Tech on Boston Scientific August 21 volume' href='https://ts2.tech/en/boston-scientific-rebounds-2-recovering-38-of-thursdays-selloff/'>in the volume summary.
Despite the rebound, the stock still finished the week down 2.82 percent, highlighting that the recovery has only partially offset the earlier drop and leaving the shares below the average and median analyst targets cited in recent data S&P Global data collected by StockAnalysis in an article hosted on ts2.tech title='TS2.Tech on Boston Scientific weekly performance' href='https://ts2.tech/en/boston-scientific-rebounds-2-recovering-38-of-thursdays-selloff/'>in the performance table.
That pattern - a heavy-volume selloff followed by a partial recovery within a week in which the stock still declines overall - often reflects short-term repositioning rather than a fundamental shift, especially when consensus estimates continue to imply double-digit upside from the latest close.
Revenue and investment profile
A recent device-focused analysis hosted on Trefis title='Trefis overview of Boston Scientific financials' href='https://www.trefis.com/stock/bsx/articles/612406/are-you-still-holding-boston-scientific-stock-for-its-next-device/2026-08-21'>Trefis points out that Boston Scientific generated $21 billion of revenue over the latest twelve-month period they reviewed, underlining the scale of its global cardiovascular and other interventional device franchise.
In the same period, the company invested $2.7 billion in capital expenditures and $2.2 billion in research and development, signaling a strategic emphasis on pipeline expansion and manufacturing capacity in support of long-term growth Trefis title='Trefis on Boston Scientific capex and R&D' href='https://www.trefis.com/stock/bsx/articles/612406/are-you-still-holding-boston-scientific-stock-for-its-next-device/2026-08-21'>in the spending breakdown.
Taken together, those figures indicate that Boston Scientific is allocating nearly one quarter of its annual revenue to investment and innovation, a level that aligns with its positioning in competitive device markets such as coronary stents, structural heart therapies, and neuromodulation.
Consensus view and rating mix
The TS2.Tech analyst summary notes that in August 2026, 26 out of 31 analysts covering Boston Scientific rated the stock as Buy or Strong Buy, with five assigning Hold ratings S&P Global data collected by StockAnalysis in an article hosted on ts2.tech title='TS2.Tech on Boston Scientific analyst rating mix' href='https://ts2.tech/en/boston-scientific-rebounds-2-recovering-38-of-thursdays-selloff/'>in the rating distribution.
That distribution translates to a coverage universe in which more than four fifths of analysts maintain positive recommendations, consistent with the consensus and median price targets that stand well above the latest trading level S&P Global data collected by StockAnalysis in an article hosted on ts2.tech title='TS2.Tech on Boston Scientific buy ratings share' href='https://ts2.tech/en/boston-scientific-rebounds-2-recovering-38-of-thursdays-selloff/'>as summarized in the data.
For retail investors, this mix of ratings illustrates how the street still views Boston Scientific as a growth-oriented device name, while the presence of several Hold calls acknowledges valuation and execution risks after the stock's multi-year run.
Device franchise and Watchman platform
Boston Scientific's portfolio spans interventional cardiology, endoscopy, peripheral interventions, and neuromodulation, but one of its signature platforms in recent years has been its Watchman left atrial appendage closure device for stroke risk reduction in atrial fibrillation patients.
The Watchman franchise has helped Boston Scientific capture share in structural heart therapies by offering an implant that can reduce reliance on long-term oral anticoagulants for selected patients, a proposition that resonates with both physicians and payers in markets with aging populations and high stroke risk.
In recent disclosures and product commentary, Boston Scientific has highlighted ongoing innovation in procedural tools and device iterations around Watchman, with an eye toward improving implantation efficiency and patient outcomes as adoption expands across geographies.
Boston Scientific stock and current price context
Boston Scientific stock trades on the New York Stock Exchange under the ticker BSX, with the most recent confirmed close at $50.37 as of August 21, 2026, 4:00 p.m. ET, according to the TS2.Tech market recap S&P Global data collected by StockAnalysis in an article hosted on ts2.tech title='TS2.Tech on Boston Scientific August 21 close' href='https://ts2.tech/en/boston-scientific-rebounds-2-recovering-38-of-thursdays-selloff/'>in the price table.
At that level, the shares sit below both the $62.69 consensus target and the $60 median target cited in analyst data, leaving room for potential upside if the company continues to deliver on its device pipeline and revenue trajectory while managing costs and capital allocation.
Fact box
Company: Boston Scientific Corp.
ISIN: US10117L1017
Ticker: BSX
Exchange: New York Stock Exchange
Price (as of August 21, 2026, 4:00 p.m. ET): $50.37 USD
Sector / Industry: Health care equipment and supplies
